These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36879663)

  • 41. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.
    Gleissner B; Siehl J; Korfel A; Reinhardt R; Thiel E
    Neurology; 2002 Feb; 58(3):390-6. PubMed ID: 11839837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
    Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
    J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study.
    Cao J; Li S; Li D; Hua W; Guo L; Xia Z
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exosomal miR-200c and miR-141 as cerebrospinal fluid biopsy biomarkers for the response to chemotherapy in primary central nervous system lymphoma.
    Hu Y; Zhang Q; Wu Z; Chen K; Xu X; Ma W; Chen B; Jin L; Guan M
    Discov Oncol; 2023 Nov; 14(1):205. PubMed ID: 37971595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.
    Zhai Y; Zhou X; Wang X
    Ther Adv Med Oncol; 2022; 14():17588359221093745. PubMed ID: 35558005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacotherapy of primary CNS lymphoma.
    Park DM; Abrey LE
    Expert Opin Pharmacother; 2002 Jan; 3(1):39-49. PubMed ID: 11772332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
    Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
    Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
    Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
    J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of immunohistochemical subtypes based on the stage of B-cell differentiation in primary CNS lymphoma.
    Inoue A; Ohnishi T; Kohno S; Matsumoto S; Nishikawa M; Ohue S; Ozaki S; Suehiro S; Kurata M; Fukushima M; Kitazawa R; Shigekawa S; Watanabe H; Kunieda T
    Int J Clin Exp Pathol; 2019; 12(4):1457-1467. PubMed ID: 31933963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma.
    Yadav BS
    World J Clin Oncol; 2024 Mar; 15(3):371-374. PubMed ID: 38576595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
    J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
    Kiefer T; Krüger WH; Montemurro M; Schüler F; Hirt C; Pasold R; Niederwieser D; Schwenke M; Dölken G
    Transfusion; 2008 Dec; 48(12):2624-8. PubMed ID: 18801020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma].
    Pang DW; Chen FL; Guo HG; Jiang XM; Wei XJ; Liu SC; Huang L; Liang ZL; Li WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1175-1180. PubMed ID: 34362499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
    Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
    Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of additional radiotherapy for primary central nervous system lymphoma.
    Zacher J; Kasenda B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
    Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
    Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Rare Presentation of Primary Central Nervous System Lymphoma in an Immunocompetent Patient.
    DeRon N; Ahmed M; Lopez D; Alobaidi A
    Cureus; 2022 Apr; 14(4):e23858. PubMed ID: 35530884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-time intracranial pressure monitoring during high-dose methotrexate treatment for primary central nervous system lymphoma.
    Dono A; Husein N; Ybarra C; Hasbun R; Choi HA; Ballester LY; Esquenazi Y
    Cancer Treat Res Commun; 2020; 25():100234. PubMed ID: 33161322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.